PT  - JOURNAL ARTICLE
AU  - Emmanuel Itti
AU  - Malik E. Juweid
AU  - Corinne Haioun
AU  - Imene Yeddes
AU  - Fatma Hamza-Maaloul
AU  - Intidhar El Bez
AU  - Eva Evangelista
AU  - Chieh Lin
AU  - Jehan Dupuis
AU  - Michel Meignan
TI  - Improvement of Early <sup>18</sup>F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background
AID  - 10.2967/jnumed.110.080556
DP  - 2010 Dec 01
TA  - Journal of Nuclear Medicine
PG  - 1857--1862
VI  - 51
IP  - 12
4099  - http://jnm.snmjournals.org/content/51/12/1857.short
4100  - http://jnm.snmjournals.org/content/51/12/1857.full
SO  - J Nucl Med2010 Dec 01; 51
AB  - This study investigated whether the reference background above which a residual mass is considered positive in the International Harmonization Project criteria should be modified for early 18F-FDG PET evaluation. Methods: In 92 patients with newly diagnosed diffuse large B-cell lymphoma, the maximal standardized uptake value (SUVmax) was measured on post–cycle 2 PET in the most intense residual mass (or, in the case of negative PET findings, in the area of most intense tumor uptake before therapy), in the mediastinal blood pool (MBP) and the liver, as potential reference background tissues. Results: With MBP as a reference (SUVmax, 2.0 ± 0.6), PET was unable to distinguish early responders from nonresponders. In contrast, with liver as a reference (SUVmax, 2.5 ± 0.7), 2-y progression-free survival was significantly different between patients with PET-negative findings (81.8% [95% confidence interval, 71%–93%]) and patients with PET-positive findings (51.8% [95% confidence interval, 35%–69%], P = 0.003). Conclusion: When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.